Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

Award Number: R44TR002692
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/15/2019
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds - ABSTRACT Antisense oligonucleotides (ASOs), siRNA and splice switching oligonucleotides (SSOs) all have immense potential as therapeutic agents, potential that is now being validated as oligonucleotides enter the clinic. SSOs in particular possess great therapeutic flexibility since they can be used to increase, decrease or alter the pattern of mRNA expression. However, progress in oligonucleotide-based therapeutics has been limited by the difficulty in delivering these complex molecules to their sites of action in the cytosol or nucleus of cells within specific tissues. There are two aspects to the delivery problem. The first is that most types of oligonucleotides have poor uptake into non-hepatic tissues such as the lung. The second is that much of the oligonucleotide that is taken up by cells is entrapped in endosomes where it is pharmacologically inert. Initos Pharmaceuticals has developed a dual approach that overcomes both aspects of the oligonucleotide delivery problem, focusing particularly on SSOs. First, we make use of SSOs comprised of peptide-morpholino oligonucleotide conjugates (P-PMOs) that have greater cell uptake and a broader tissue distribution than conventional oligonucleotides. Second, Initos has addressed the intracellular delivery issue by creating novel proprietary oligonucleotide enhancing compounds (OECs) that mobilize all types of oligonucleotides from endosomes thus significantly increasing their therapeutic effects. While the P-PMO/SSO+OEC combination is a platform technology applicable in many therapeutic contexts, this proposal focuses on two challenging problems in pulmonary disease. First, we will address the correction of splicing mutations in cystic fibrosis patients who are refractory to current therapies including modulator drugs. Second, we will use the P-PMO/SSO+OEC combination to reduce the hypersecretion of mucins MUC5AC or MUC5B that is characteristic of several major airway diseases including asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF). During our current Phase I STTR we established proof of concept for the P-PMO/SSO+OEC technology by showing: (a) correction of splicing in lungs in a murine reporter model; (b) correction of splicing and restoration of function in CF patient-derived differentiated airway cells; (c) dramatic reduction of MUC5AC expression in human cells. In our Phase II SBIR application we propose IND-facilitating development of our unique P- PMO/SSO+OEC technology. The goal is to identify P-PMO/SSO+OEC entities that are highly efficacious and minimally toxic by optimization of composition, dose, timing and route of administration. The deliverables for the proposed project are the development for pre-IND evaluation of P-PMO/SSO+OEC entities for therapy of a CF splicing mutation and for reduction of MUC5AC or MUC5B hypersecretion.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$186,489 )
2024	2021	INITOS PHARMACEUTICALS LLC	408 LYONS RD	CHAPEL HILL	NC	27514	ORANGE	USA	National Center for Advancing Translational Sciences	000	3	2/16/2024	NON-COMPETING CONTINUATION	-$186,489
														Subtotal = -$186,489

Issue Date FY: 2021 ( Subtotal = $888,678 )
2021	2021	INITOS PHARMACEUTICALS LLC	408 LYONS RD	CHAPEL HILL	NC	27514	ORANGE	USA	National Center for Advancing Translational Sciences	001	3	8/6/2021	NON-COMPETING CONTINUATION	$888,678
2021	2020	INITOS PHARMACEUTICALS LLC	408 LYONS RD	CHAPEL HILL	NC	27514	ORANGE	USA	National Center for Advancing Translational Sciences	000	2	12/1/2020	COMPETING CONTINUATION	$0
														Subtotal = $888,678

Issue Date FY: 2020 ( Subtotal = $838,276 )
2020	2020	INITOS PHARMACEUTICALS LLC	408 LYONS RD	CHAPEL HILL	NC	27514	ORANGE	USA	National Center for Advancing Translational Sciences	000	2	7/23/2020	COMPETING CONTINUATION	$838,276
														Subtotal = $838,276

Grand Total All Awards = $1,540,465

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

Award Number: R44TR002692

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/15/2019

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer